Portfoliotracker

Replimune Group, Inc.

REPL · NASDAQGS · Healthcare Biotechnology 5/100 E

21,41 $
▼ −0,48 (−2,19 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 11:55
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score5 / 100 Market cap2,25 mld. $ P/E– Forward P/E-31,9 P/S– P/B11,0 EV/EBITDA– Dividend yield– FCF yield-10,91 % EPS-2,73 $ Net margin0,0 % Return on equity-115,8 % Beta0,93 Debt / equity0,62
52-week range 1,50 to 23,54
3-month average volume2,6 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Employees
465
Country
United States
Fiscal year end
31. 3.
Data since
20. 7. 2018

Explore further

Similar companies SRRKSNDXSTOKKURAIDYA

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account